In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across workflows, and FDA's approval of a gene therapy for a rare childhood syndrome.
News|Podcasts|June 24, 2026
ACT Brief: Operation TrialBlazer Launched, Protocol Complexity Rising, and Data Infrastructure for AI
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine HHS coordinated effort to restore US clinical research leadership, two decades of rising protocol complexity, and data architecture frameworks for AI sustainability.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- HHS
launched Operation TrialBlazer, a coordinated FDA and NIH effort to reduce US trial friction and counter China's growing clinical research share. The initiative includes an Expedited IND pilot with rolling institutional submissions, a Phase I Contact Center, updated CMC guidance for early-stage trials, and single-trial approval flexibility for late-stage programs. - New
research published on ACT examined protocol complexity across 190,000 trials from 2004–2025, finding endpoints doubled from median 3 to 7, driven almost entirely by secondary endpoints. Failure rates rose modestly from 10.2% to 13.2%, with Phase II consistently the highest-failure phase and oncology now representing 34% of clinical trial activity. - In a Pharmaceutical Technology
article , Partha Anbil and Vineet Kumar evaluated three clinical data management architectures—warehouses, lakes, and lakehouses—using FAIR principles plus the 5 V's framework to guide selection for bias-controlled, interoperable AI development.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are formalizing patient input requirements.
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more than sourcing strategy, and how early readiness signals predict trial risk.
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
In today's ACT Brief, we examine what families with rare epilepsy teach about trial feasibility, how preclinical CRO partnerships are evolving beyond transactional services, and why cortisol dysregulation limits GLP-1 effectiveness in diabetes.
In today's ACT Brief, we examine how shifting patient engagement to endpoint selection improves trial data quality, why execution infrastructure must precede AI deployment, and addressing missing baseline data in real-world oncology research.
In today's ACT Brief, we examine why seizure reduction misses what families want from epilepsy trials, how lab coordination requires connecting data to intent, and why healthcare needs orchestration rather than more tools.
In today's ACT Brief, we examine genuine patient partnership in trial design, how AI enables informed recruitment while preserving clinician relationships, and moving patient engagement beyond performative gestures.
Trending on Applied Clinical Trials Online
1
Four Years After Disrupting Clinical Trial Diversity at DPHARM, Acclinate Is Back to Disrupt the Data Behind It
2
How a Platform Approach Can Scale AI’s Impact in Life Sciences
3
DPHARM 2026: Why Making Technology Easier Isn't Enough for Sites
4
DPHARM 2026: What the Patient-Site Relationship Needs Most Right Now
5